TITLE

Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice

AUTHOR(S)
Thulesen, J.; Hartmann, B.; Hare, K. .J.; Kissow, H.; Ørskov, C.; Holst, J. J.; Poulsen, S. S.
PUB. DATE
August 2004
SOURCE
Gut;Aug2004, Vol. 53 Issue 8, p1145
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Glucagon-like peptide 2 (GLP-2) is an intestinotrophic mediator with therapeutic potential in conditions with compromised intestinal capacity. However, growth stimulation of the intestinal system may accelerate the growth of existing neoplasms in the intestine. Aims: In the present study, the effects of GLP-2 treatment on the growth of chemically induced colonic neoplasms were investigated. Methods: In 210 female C57b1 mice, colonic tumours were initially induced with the methylating carcinogen 1 ,2-dimethylhydrazine (DMH) and mice were then treated with GLP-2. Two months after discontinuation of the carcinogen treatment, 135 of the mice were allocated to one of six groups which were treated twice daily with 25 μg GLP-2, 25 μg Gly2-GLP-2 (stable analogue), or phosphate buffered saline for a short (10 days) or long (one month) period. The remaining 75 mice had a treatment free period of three months and were then allocated to groups subjected to long term treatment, as above. Results: Colonic polyps developed in 100% of the mice, regardless of treatment. Survival data revealed no statistical significant differences among the different groups but histopathological analysis demonstrated a clear and significant increase in tumour load of mice treated with Gly2-GLP-2. The tumour promoting effect of native GLP-2 was less pronounced but the number of small sized polyps increased following long term treatment. Conclusions: The present results clearly indicate that GLP-2 promotes the growth of mucosal neoplasms. Our findings highlight the need for future investigations on the effects of GLP-2 in conditions needing long time treatment or with increased gastrointestinal cancer susceptibility.
ACCESSION #
13986666

 

Related Articles

  • Reversal of Obesity and Insulin Resistance by a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist in Diet-Induced Obese Mice. Min He; Haoran Su; Weiwei Gao; Johansson, Stina M.; Qing Liu; Xiaoyan Wu; Jiayu Liao; Young, Andrew A.; Tamas Bartfai; Ming-Wei Wang // PLoS ONE;2010, Vol. 5 Issue 12, p1 

    Background: Glucagon-like peptide-1 (GLP-1) is recognized as an important regulator of glucose homeostasis. Efforts to utilize GLP-1 mimetics in the treatment of diabetes have yielded clinical benefits. A major hurdle for an effective oral therapy has been the difficulty of finding a...

  • Increased intracellular content of enteroglucagon in proximal colon is related to intestinal adaptation to germ-free status. Arantes, R. M. E.; Nogueira, A. M. M. F. // Cell & Tissue Research;Mar2001, Vol. 303 Issue 3, p447 

    Changes in the frequency of endocrine cells are evidence of intestinal adaptation to germ-free (GF) status. Not only the distribution of these cells along the intestine, but also the differences in intracellular content of these regulatory peptides may be explored to explain functional and...

  • Glucagon attenuates the action of insulin on glucose output in the liver of the Goto-Kakizaki rat perfused in situ. Doi, Yasuko; Iwai, Masaru; Matsuura, Bunzou; Onji, Morikazu // Pflugers Archiv European Journal of Physiology;Jul2001, Vol. 442 Issue 4, p537 

    The effects of glucagon and insulin on glucose production were explored directly using the isolated perfused liver of the Goto-Kakizaki (GK) rat, an animal model of type-2 diabetes. In the perfused liver of control rats, infusion of glucagon (0.06–1.0 nM) into the portal vein...

  • GLUCAGON. Schnell, Zoanne Burgess; Van Leeuwen, Anne M.; Kranpitz, Todd R. // Davis's Comprehensive Handbook of Laboratory & Diagnostic Tests ;Jan2003, p534 

    Presents a laboratory and diagnostic guide for testing glucagon, a hormone secreted by the alpha cells of the islets of Langerhans in the pancreas in response to hypoglycemia. Clinical indications of glucagon; Outcome of the increased or decreased level of glucagon; Factors which may interfere...

  • glucagon.  // Royal Society of Medicine: Medicines;2002, p269 

    This article presents information on glucagon, a hormone produced and secreted by the pancreas in order to cause an increase in blood sugar levels. Therapeutically, glucagon can be administered to patients with hypoglycaemia in an emergency, but it is mainly used for diagnostic purposes....

  • Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. Knauf, Claude; Cani, Patrice D.; Perrin, Christophe; Iglesias, Miguel A.; Maury, Jean François; Bernard, Elodie; Benhamed, Fadilha; Grémeaux, Thierry; Drucker, Daniel J.; Kahn, C. Ronald; Girard, Jean; Tanti, Jean François; Delzenne, Nathalie M.; Postic, Catherine; Burcelin, Rémy // Journal of Clinical Investigation;Dec2005, Vol. 115 Issue 12, p3554 

    Intestinal glucagon-like peptide-1 (GLP-1) is a hormone released into the hepatoportal circulation that stimulates pancreatic insulin secretion. GLP-1 also acts as a neuropeptide to control food intake and cardiovascular functions, but its neural role in glucose homeostasis is unknown. We show...

  • Glucagon.  // Encyclopedic Reference of Molecular Pharmacology;2004, p405 

    A definition of the term "glucagon" is presented. It refers to a single chain 21 amino acid polypeptide, which is synthesized mainly in the A-cells of the pancreatic islets as well as in the stomach. Glucose or fatty acids in the plasma either stimulates or inhibits glucagon secretion. The...

  • Glucagon-like Peptide-1.  // Encyclopedic Reference of Molecular Pharmacology;2004, p405 

    A definition of the term "glucagon-like peptide-1" (GLP1) is presented. Glucagon, GLP1 and GLP2 are three peptide hormones generated by a cleavage of a common precursor polypeptide. GLP1 stimulates insulin secretion from pancreatic B cells and inhibits feeding in fasted rats when injected into...

  • Glucagon and gastrin secretion by a pancreatic tumour and its metastases. Wood, S. M.; Bloom, S. R. // Journal of the Royal Society of Medicine;Jan1982, Vol. 75 Issue 1, p42 

    The article presents a medical case of a 65-year-old with a pancreatic tumor and hepatic metastases secreting three different peptides such as glucagon, gastrin and pancreatic polypeptide. The patient described is unusual in that he developed the features of both the glucagonoma syndrome and the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics